93 related articles for article (PubMed ID: 8763810)
41. Induction of antitumor immunity against cervical cancer by protein HPV-16 E7 in fusion with ricin B chain in tumor-bearing mice.
Sadraeian M; Rasoul-Amini S; Mansoorkhani MJ; Mohkam M; Ghoshoon MB; Ghasemi Y
Int J Gynecol Cancer; 2013 Jun; 23(5):809-14. PubMed ID: 23574882
[TBL] [Abstract][Full Text] [Related]
42. Multiple mechanisms underlie HLA dysregulation in cervical cancer.
Brady CS; Bartholomew JS; Burt DJ; Duggan-Keen MF; Glenville S; Telford N; Little AM; Davidson JA; Jimenez P; Ruiz-Cabello F; Garrido F; Stern PL
Tissue Antigens; 2000 May; 55(5):401-11. PubMed ID: 10885560
[TBL] [Abstract][Full Text] [Related]
43. Dendritic cell-based tumor vaccine for cervical cancer I: in vitro stimulation with recombinant protein-pulsed dendritic cells induces specific T cells to HPV16 E7 or HPV18 E7.
Nonn M; Schinz M; Zumbach K; Pawlita M; Schneider A; Dürst M; Kaufmann AM
J Cancer Res Clin Oncol; 2003 Sep; 129(9):511-20. PubMed ID: 12905010
[TBL] [Abstract][Full Text] [Related]
44. Antibodies to human papillomavirus type 16 in patients with cervical neoplasia.
Reeves WC; Rawls JA; Green M; Rawls WE
Lancet; 1990 Mar; 335(8688):551-2. PubMed ID: 1689789
[No Abstract] [Full Text] [Related]
45. [Progress in immunological studies of women with genital neoplasms].
Paruch J
Przegl Lek; 1982; 39(6):441-7. PubMed ID: 6753040
[No Abstract] [Full Text] [Related]
46. [Recombinant therapeutic vaccines against cancer of the uterine cervix].
Berumen J; Villegas N
Salud Publica Mex; 1997; 39(4):288-97. PubMed ID: 9381250
[TBL] [Abstract][Full Text] [Related]
47. Cervical cancer cells suppress effector functions of cytotoxic T cells through the adenosinergic pathway.
Mora-García ML; Ávila-Ibarra LR; García-Rocha R; Weiss-Steider B; Hernández-Montes J; Don-López CA; Gutiérrez-Serrano V; Titla-Vilchis IJ; Fuentes-Castañeda MC; Monroy-Mora A; Jave-Suárez LF; Chacón-Salinas R; Vallejo-Castillo L; Pérez-Tapia SM; Monroy-García A
Cell Immunol; 2017 Oct; 320():46-55. PubMed ID: 28950987
[TBL] [Abstract][Full Text] [Related]
48. [Cervical cancer: new testing strategies?].
Heard I; Costagliola D
Med Sci (Paris); 2008 Nov; 24(11):977-8. PubMed ID: 19038102
[No Abstract] [Full Text] [Related]
49. Increased sensitivity of radiated murine cervical cancer tumors to E7 subunit vaccine-driven CTL-mediated killing induces synergistic anti-tumor activity.
Ye GW; Park JB; Park YJ; Choi YS; Sin JI
Mol Ther; 2007 Aug; 15(8):1564-70. PubMed ID: 17505485
[TBL] [Abstract][Full Text] [Related]
50. Combining MPDL3280A with adoptive cell immunotherapy exerts better antitumor effects against cervical cancer.
Zheng Y; Yang Y; Wu S; Zhu Y; Tang X; Liu X
Bioengineered; 2017 Jul; 8(4):367-373. PubMed ID: 27754760
[TBL] [Abstract][Full Text] [Related]
51. Specificity of human cytotoxic T lymphocytes induced by a human papillomavirus type 16 E7-derived peptide.
Jochmus I; Osen W; Altmann A; Buck G; Hofmann B; Schneider A; Gissmann L; Rammensee HG
J Gen Virol; 1997 Jul; 78 ( Pt 7)():1689-95. PubMed ID: 9225046
[TBL] [Abstract][Full Text] [Related]
52. Human papillomaviruses: their clinical significance in the management of cervical carcinoma.
Hines JF; Jenson AB; Barnes WA
Oncology (Williston Park); 1995 Apr; 9(4):279-85; discussion 286-8, 291. PubMed ID: 7547192
[TBL] [Abstract][Full Text] [Related]
53. [Preventive vaccines and immunotherapy clinical trials against cervical cancer].
Valdespino-Gómez VM
Cir Cir; 2005; 73(1):57-69. PubMed ID: 15888272
[TBL] [Abstract][Full Text] [Related]
54. [Immune response of patients with carcinoma of uterine cervix treated by radiotherapy and a preliminary report on immunotherapy].
Ma J
Zhonghua Zhong Liu Za Zhi; 1984 Mar; 6(2):120-3. PubMed ID: 6468252
[No Abstract] [Full Text] [Related]
55. Clinical Trials Referral Resource. Clinical trials in cervical cancer.
Trimble EL; Schoenfeldt M; Streicher H; Gius D; Cornelison TL
Oncology (Williston Park); 2003 Jan; 17(1):84-9. PubMed ID: 12599933
[No Abstract] [Full Text] [Related]
56. [Ⅰ. Immunotherapy in Cervical Cancer-Current Approaches and Future Horizons].
Iwata T; Matsui T; Matsuda R; Katoh Y; Sugawara M; Nogami Y; Nishio H; Yamagami W
Gan To Kagaku Ryoho; 2024 Feb; 51(2):134-137. PubMed ID: 38449397
[No Abstract] [Full Text] [Related]
57. [Ⅲ.The Current Status and Future Perspective of Chemotherapy, Targeted Therapy and Immunotherapy for Cervical Cancer].
Yabuno A; Hasegawa K
Gan To Kagaku Ryoho; 2020 Feb; 47(2):242-246. PubMed ID: 32381956
[No Abstract] [Full Text] [Related]
58. CALLA trial: immunotherapy in locally advanced cervical cancer - Authors' reply.
Monk BJ; Mayadev J
Lancet Oncol; 2024 Mar; 25(3):e96. PubMed ID: 38423064
[No Abstract] [Full Text] [Related]
59. CONSENSUS REPORT ON THE PREVENTION, DIAGNOSIS, AND TREATMENT OF CERVICAL CANCER - A PERSPECTIVE FROM THE IMMUNE SYSTEM TOWARD IMMUNOTHERAPY.
Cetina-Pérez L; Castro-Eguiluz D
Rev Invest Clin; 2020; 72(4):185-187. PubMed ID: 33064681
[No Abstract] [Full Text] [Related]
60. Prospects for immunotherapy in cervical cancer.
Immunol Today; 1996 Jul; 17(7):299. PubMed ID: 8763810
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
